Regeneron Pharmaceuticals, Inc.
REGN
$527.78
-$19.89-3.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 808.70M | 917.70M | 1.34B | 1.43B | 722.00M |
| Total Depreciation and Amortization | 126.90M | 126.40M | 121.70M | 120.70M | 114.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -20.10M | 305.10M | -107.20M | -290.50M | 235.90M |
| Change in Net Operating Assets | 129.60M | -86.40M | -63.90M | -908.50M | 440.50M |
| Cash from Operations | 1.05B | 1.26B | 1.29B | 354.00M | 1.51B |
| Capital Expenditure | -229.30M | -199.60M | -241.90M | -180.50M | -133.90M |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 20.10M | -- |
| Cash Acquisitions | -- | -11.50M | 0.00 | -5.00M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 876.80M | 561.70M | -332.50M | -391.80M | -1.55B |
| Cash from Investing | 647.50M | 350.60M | -574.40M | -557.20M | -1.69B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 60.60M | 90.90M | 254.70M | 437.60M | 682.10M |
| Repurchase of Common Stock | -1.05B | -1.23B | -855.30M | -915.70M | -635.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -93.80M | -- | -- | -- | -- |
| Other Financing Activities | -10.30M | 0.00 | -33.40M | -- | -- |
| Cash from Financing | -1.09B | -1.14B | -634.00M | -478.10M | 47.10M |
| Foreign Exchange rate Adjustments | 600.00K | -700.00K | 800.00K | -300.00K | -500.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 604.00M | 477.20M | 83.60M | -681.60M | -128.00M |